Cholangiocarcinoma
49 programs · 46 companies
Programs
49
Companies
46
Trials
43
MOAs
32
HER2FcRniFXIaiSHP2iIL-23iCDK4/6iPLK4iEZH2iSOS1iTROP-2 ADC
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-7254 | Phase 2 | CFTR | ||
| Suracagene | Phase 3 | PRMT5 | ||
| TAK-8730 | Phase 2 | VEGF | ||
| VRT-1576 | Phase 2/3 | RET | ||
| Zenotapinarof | Preclinical | CD38 | ||
| Terazumab | NDA/BLA | CD47 | ||
| STO-2663 | Approved | LAG-3 | ||
| Miritapinarof | Phase 2 | IL-17A | ||
| XTA-4333 | Approved | FcRn | ||
| Sovalucimab | NDA/BLA | TROP-2 | ||
| IMV-6752 | Phase 2 | CDK2 | ||
| Daranesiran | Phase 2/3 | CGRP | ||
| Terafotisoran | Phase 1 | IL-13 | ||
| APT-892 | Approved | PD-1 | ||
| XBI-3618 | Phase 1 | GIP-R | ||
| Lisozanubrutinib | Approved | EGFR | ||
| Bemasertib | Phase 1 | PLK4 | ||
| Capitapinarof | Preclinical | KIF18A | ||
| Doxazanubrutinib | Phase 1 | BCL-2 | ||
| Pexaderotide | Phase 3 | PARP | ||
| INT-430 | Phase 2/3 | CD19 | ||
| Kematinib | Approved | KIF18A | ||
| Mavutuximab | Phase 1 | TIGIT | ||
| HAR-9296 | Phase 1 | CD19 | ||
| ENC-4310 | Phase 1/2 | TROP-2 | ||
| GEN-IIT-955 | Phase 2/3 | CD19 | ||
| Poladerotide | Phase 1/2 | SMN2 | ||
| HYK-8507 | Phase 1 | GLP-1R | ||
| MEI-1324 | Preclinical | KRASG12C | ||
| Ribotapinarof | NDA/BLA | MET | ||
| AUR-9187 | Phase 2 | PD-L1 | ||
| Rimanesiran | Phase 2/3 | SGLT2 | ||
| MOR-1300 | Phase 1/2 | EZH2 | ||
| Geliderotide | Phase 2 | SMN2 | ||
| Adagrainavolisib | Phase 2 | APOC3 | ||
| Daranesiran | Preclinical | IL-17A | ||
| Olpazasiran | Phase 3 | FcRn | ||
| MYG-2072 | Phase 2 | Aβ | ||
| PHL-685 | Approved | USP1 | ||
| KLB-5656 | Phase 1 | GLP-1R | ||
| Rimalucimab | Phase 2/3 | KIF18A | ||
| BRK-7538 | Phase 2/3 | DLL3 | ||
| BRK-5301 | Preclinical | PCSK9 | ||
| Doxacilimab | NDA/BLA | HER2 | ||
| RIC-4332 | Phase 3 | CD123 | ||
| Riboosocimab | Phase 2 | CD3 | ||
| Rilulemzoparlimab | Approved | KIF18A | ||
| Gozeinavolisib | Phase 2/3 | USP1 | ||
| DYN-8432 | Phase 1/2 | USP1 |
Trials (43)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07235590 | TAK-8730 | Phase 2 | Terminated |
| NCT05811085 | VRT-1576 | Phase 2/3 | Not yet recr... |
| NCT08329761 | Zenotapinarof | Preclinical | Not yet recr... |
| NCT05272340 | STO-2663 | Approved | Active |
| NCT05539246 | IMV-6752 | Phase 2 | Terminated |
| NCT08361093 | APT-892 | Approved | Terminated |
| NCT03930789 | XBI-3618 | Phase 1 | Completed |
| NCT06449016 | Capitapinarof | Preclinical | Recruiting |
| NCT08884888 | Capitapinarof | Preclinical | Completed |
| NCT05973124 | Doxazanubrutinib | Phase 1 | Active |
| NCT06998878 | Pexaderotide | Phase 3 | Terminated |
| NCT08524402 | Pexaderotide | Phase 3 | Completed |
| NCT05659076 | Pexaderotide | Phase 3 | Recruiting |
| NCT06493838 | Pexaderotide | Phase 3 | Not yet recr... |
| NCT04681151 | Kematinib | Approved | Recruiting |
| NCT06422869 | Kematinib | Approved | Recruiting |
| NCT03747819 | Kematinib | Approved | Recruiting |
| NCT06547809 | Kematinib | Approved | Completed |
| NCT07196051 | HAR-9296 | Phase 1 | Terminated |
| NCT06663954 | ENC-4310 | Phase 1/2 | Active |